Our Stories
Aspen reaches more than 920 000 beneficiaries through Mandela Day
Aspen is marking the 16th consecutive year of its Mandela Day campaign which has reached more than 920 000 beneficiaries over this period.
Transactions
Aspen Announces Successful Completion of Aspen APAC Divestment
Aspen Pharmacare Holdings Limited (“Aspen”) today announced the successful completion of the divestment of its Asia Pacific (“APAC”) business comprising Australia, New Zealand and other Asia Pacific regions (excluding China)
Press Releases
Aspen and Africa CDC advance long-term Vaccine Supply Partnership for Africa
Aspen Pharmacare (“Aspen”) and Africa Centres for Disease Control and Prevention (“Africa CDC”) are in advanced discussions on a long-term demand and supply alignment framework aimed at strengthening sustainable vaccine manufacturing in Africa.
Financial
Aspen delivers encouraging results, driven by strong Commercial Pharma, reshaped Manufacturing and value realisation from APAC divestment
Aspen Pharmacare Holdings has reported unaudited Group interim financial results for the six months ended 31 December 2025.
Transactions
Proposed divestment of Aspen Asia Pacific (excluding China) for R26.5 billion
Aspen Holdings, through its wholly owned subsidiary Aspen Global Incorporated, has entered into binding agreements for the 100% sale of Aspen Asia Pacific (excluding China) for R26.5 billion.
Press Releases
Stephen Saad receives both AABLA Lifetime Achievement Award and African of the Year Award
Stephen Saad was presented with the prestigious Lifetime Achievement Award as well as the African of the Year Award at the 13th All Africa Business Leader Awards on 12 November 2025
Press Releases
Aspen highlights the rising diabetes disease burden
Aspen marked World Diabetes Day by highlighting the alarming economic, social, productivity and reduced life expectancy impact that diabetes is having on South Africa
Financial
Aspen building momentum in Commercial Pharmaceuticals and Manufacturing strategy modified
Aspen Pharmacare Holdings has reported financial results for the year ended 30 June 2025, with strong momentum in Commercial Pharmaceuticals and a modified Manufacturing strategy.
Media Enquiries
Shauneen Beukes
Group Communications Consultant
+27 31 580 8600
+27 82 389 8900
sbeukes@aspenpharma.com